References
- Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin
in patients with atrial fibrillation N Engl J Med . 2009;361 (12): 1139-1151. doi:10.1056/NEJMoa0905561
- Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in
nonvalvular atrial fibrillation. N Engl J Med . 2011;365 (10): 883-891. doi:10.1056/NEJMoa1009638
- Hori M, Matsumoto M, Tanahashi N, et al. Rivaroxaban vs. warfarin in
Japanese patients with atrial fibrillation – the J-ROCKET AF study
–. Circ J . 2012; 76 (9): 2104-2111.
doi:10.1253/circj.cj-12-0454
- Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin
in patients with atrial fibrillation. N Engl J Med . 2011;365 (11): 981-992. doi:10.1056/NEJMoa1107039
- Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in
patients with atrial fibrillation. N Engl J Med . 2013;369 (22): 2093-2104. doi:10.1056/NEJMoa1310907
- U.S. Department of Health and Human Services, Food and Drug
Administration, Center for Drug Evaluation and Research, and Center
for Biologics Evaluation and Research, Enhancing the diversity of
clinical trial populations — eligibility criteria, enrollment
practices, and trial design guidance for industry, November 2020.
- ICH Steering Committee, ICH harmonized tripartite guideline general
considerations for clinical trials, 17 July 1997
- Lee S, Monz BU, Clemens A, Brueckmann M, Lip GY. Representativeness of
the dabigatran, apixaban and rivaroxaban clinical trial populations to
real-world atrial fibrillation patients in the United Kingdom: a
cross-sectional analysis using the General Practice Research
Database. BMJ Open . 2012; 2 (6): e001768. Published
2012 Dec 14. doi:10.1136/bmjopen-2012-001768
- Yoon CH, Park YK, Kim SJ, et al. Eligibility and preference of new
oral anticoagulants in patients with atrial fibrillation: comparison
between patients with versus without stroke. Stroke . 2014;45 (10): 2983-2988. doi:10.1161/STROKEAHA.114.005599
- Hägg L, Johansson C, Jansson JH, Johansson L. External validity of the
ARISTOTLE trial in real-life atrial fibrillation
patients. Cardiovasc Ther . 2014; 32 (5): 214-218.
doi:10.1111/1755-5922.12087
- Desmaele S, Steurbaut S, Cornu P, Brouns R, Dupont AG. Clinical trials
with direct oral anticoagulants for stroke prevention in atrial
fibrillation: how representative are they for real life
patients? Eur J Clin Pharmacol . 2016; 72 (9):
1125-1134. doi:10.1007/s00228-016-2078-1
- Fanning L, Ilomäki J, Bell JS, Dārziņš P. The representativeness of
direct oral anticoagulant clinical trials to hospitalized patients
with atrial fibrillation. Eur J Clin Pharmacol . 2017;73 (11): 1427-1436. doi:10.1007/s00228-017-2297-0
- Hughey AB, Gu X, Haymart B, et al. Warfarin for prevention of
thromboembolism in atrial fibrillation: comparison of patient
characteristics and outcomes of the ”Real-World” Michigan
Anticoagulation Quality Improvement Initiative
(MAQI2) registry to the RE-LY, ROCKET-AF, and
ARISTOTLE trials. J Thromb Thrombolysis . 2018; 46 (3):
316-324. doi:10.1007/s11239-018-1698-y
- Morimoto T, Uchida K, Sakakibara F, Kinjo N, Ueda S. Effect of
concomitant antiplatelet therapy on ischemic and hemorrhagic events in
patients taking oral anticoagulants for nonvalvular atrial
fibrillation in daily clinical practice. Pharmacoepidemiol Drug
Saf . 2021; 30 (10): 1321-1331. doi:10.1002/pds.5228
- Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ.
Validation of clinical classification schemes for predicting stroke:
results from the National Registry of Atrial
Fibrillation. JAMA . 2001; 285 (22): 2864-2870.
doi:10.1001/jama.285.22.2864
- Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel
user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding
in patients with atrial fibrillation: the Euro Heart
Survey. Chest . 2010; 138 (5): 1093-1100.
doi:10.1378/chest.10-0134
- Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of
the Scientific and Standardization Committee of the International
Society on Thrombosis and Haemostasis. Definition of major bleeding in
clinical investigations of antihemostatic medicinal products in
non-surgical patients. J Thromb Haemost . 2005; 3 (4):
692-694. doi:10.1111/j.1538-7836.2005.01204.x
- Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in Myocardial
Infarction (TIMI) Trial, Phase I: A comparison between intravenous
tissue plasminogen activator and intravenous streptokinase. Clinical
findings through hospital discharge. Circulation .
1987;76 (1):142-154. doi:10.1161/01.cir.76.1.142
- Okumura K, Akao M, Yoshida T, et al. Low-Dose Edoxaban in Very Elderly
Patients with Atrial Fibrillation. N Engl J Med . 2020;383 (18): 1735-1745. doi:10.1056/NEJMoa2012883
- Rothwell PM. External validity of randomised controlled trials: ”to
whom do the results of this trial apply?” Lancet . 2005;365 (9453): 82-93. doi:10.1016/S0140-6736(04)17670-8